BPTH Research and Charts

BPTH - Bio-Path Holdings Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-13 (Delayed quote data 2025-06-26)

Last 0.16	Change ⇓ -0.02 (0.00%)	Volume 36,334
	Open 0.17	High 0.20	Low 0.16

8EMA (Daily) 0.18	40EMA (Daily) 0.19	50EMA (Daily) 0.20	STO (Daily) 20.476	MACD Hist (Daily) -0.007
8EMA (Weekly) 0.181	40EMA (Weekly) 1.02	50EMA (Weekly) 1.79	STO (Weekly) 56.727	MACD Hist (Weekly) 0.186


Company Profile
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.